Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nektar Therapeutics (NKTR : NSDQ)

• Company Description    Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform. Number of Employees: 61

• Price / Volume Information    Yesterday's Closing Price: $55.97 Daily Weekly Monthly 20 Day Moving Average: 881,443 shares Shares Outstanding: 19.02 (millions) Market Capitalization: $1,064.47 (millions) Beta: 1.19 52 Week High: $66.92 52 Week Low: $6.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.00% 0.30% 12 Week 105.32% 96.81% Year To Date 301.42% 250.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 455 MISSION BAY BOULEVARD SOUTH - SAN FRANCISCO,CA 94158 USA ph: 415-482-5300 fax: 415-339-5300 cdavis@lifesciadvisors.com http://www.nektar.com

• General Corporate Information    Officers Howard W. Robin - Chief Executive Officer and President Robert B. Chess - Chairman of the Board Sandra Gardiner - Interim Chief Financial Officer Jeffrey R. Ajer - Director Diana M. Brainard - Director Peer Information Nektar Therapeutics (GSAC) Nektar Therapeutics (CASI) Nektar Therapeutics (ALCD.) Nektar Therapeutics (OMNN) Nektar Therapeutics (CGPI.) Nektar Therapeutics (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 640268306 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/11/26 Share - Related Items Shares Outstanding: 19.02 Most Recent Split Date: 6.00 (0.07:1) Beta: 1.19 Market Capitalization: $1,064.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.98 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-12.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.51 Price/Cash Flow: - Price / Sales: 17.00 EPS Growth vs. Year Ago Period: 31.45% vs. Previous Quarter: 37.29% Sales Growth vs. Year Ago Period: -51.13% vs. Previous Quarter: 5.50% ROE 09/30/25 - -456.53 06/30/25 - -631.43 03/31/25 - -329.54 ROA 09/30/25 - -57.80 06/30/25 - -58.21 03/31/25 - -55.24 Current Ratio 09/30/25 - 4.24 06/30/25 - 2.61 03/31/25 - 3.24 Quick Ratio 09/30/25 - - 06/30/25 - 2.61 03/31/25 - 3.24 Operating Margin 09/30/25 - -246.77 06/30/25 - -208.87 03/31/25 - -191.73 Net Margin 09/30/25 - -192.87 06/30/25 - -163.17 03/31/25 - -152.49 Pre-Tax Margin 09/30/25 - -181.76 06/30/25 - -154.55 03/31/25 - -147.55 Book Value 09/30/25 - 4.47 06/30/25 - -1.95 03/31/25 - 1.11 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - 6.13 Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00

Powered by Zacks Investment Research ©